GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » 10-Year ROIIC %

CytoDyn (STU:296) 10-Year ROIIC % : -36.66% (As of May. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. CytoDyn's 10-Year ROIIC % for the quarter that ended in May. 2024 was -36.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for CytoDyn's 10-Year ROIIC % or its related term are showing as below:

STU:296's 10-Year ROIIC % is ranked worse than
53.08% of 1251 companies
in the Biotechnology industry
Industry Median: -29.5 vs STU:296: -36.66

CytoDyn 10-Year ROIIC % Historical Data

The historical data trend for CytoDyn's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn 10-Year ROIIC % Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -469.48 -130.10 -261.48 -105.91 -36.66

CytoDyn Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -36.66 - -

Competitive Comparison of CytoDyn's 10-Year ROIIC %

For the Biotechnology subindustry, CytoDyn's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where CytoDyn's 10-Year ROIIC % falls into.


;
;

CytoDyn 10-Year ROIIC % Calculation

CytoDyn's 10-Year ROIIC % for the quarter that ended in May. 2024 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -16.704 (May. 2024) - -5.906 (May. 2014) )/( 28.202 (May. 2024) - 2.447 (May. 2014) )
=-10.798/25.755
=-41.93%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CytoDyn  (STU:296) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


CytoDyn 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of CytoDyn's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines